New hope for advanced cervical cancer: drug combo trial launches
NCT ID NCT05990803
First seen Oct 31, 2025 · Last updated May 09, 2026 · Updated 27 times
Summary
This study tests two experimental drugs, BL-B01D1 and SI-B003, alone or together in 130 women with recurrent or metastatic cervical cancer that has not responded to standard treatments. The goal is to see if these drugs can shrink tumors or slow disease progression. Participants must be 18-75 years old and in relatively good health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.